Atypical antipsychotics for insomnia: A systematic review

Sleep Medicine

Volumn 22, Issue , 2016, Pages 13-17

  Thompson, Wade ^a,b   Quay, Teo A W ^c   Rojas Fernandez, Carlos ^d,e   Farrell, Barbara ^b,d,f   Bjerre, Lise M ^a,b,f  

^a UNIVERSITY OF OTTAWA   (Canada)

^b BRUYÈRE RESEARCH INSTITUTE   (Canada)

^c CANADIAN AGENCY FOR DRUGS AND TECHNOLOGIES IN HEALTH   (Canada)

^d UNIVERSITY OF WATERLOO   (Canada)

^e Dept Kinesiology   (Canada)

^f UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Antipsychotic agents; Insomnia; Off label use; Sleep initiation and maintenance disorders

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; HYPNOTIC AGENT; OLANZAPINE; PLACEBO; QUETIAPINE; RISPERIDONE; NEUROLEPTIC AGENT;

ADULT; ADVERSE DRUG REACTION; ARTICLE; BEDTIME DOSAGE; CASE CONTROL STUDY; COHORT ANALYSIS; CONFUSION; DAYTIME SOMNOLENCE; DISEASE SEVERITY; DRUG EFFICACY; HUMAN; INSOMNIA; NARRATIVE; PATIENT SATISFACTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY CONTROL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; SLEEP; SLEEP PARAMETERS; SLEEP TIME; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VISUAL ANALOG SCALE;

ANTIPSYCHOTIC AGENTS; HUMANS; QUETIAPINE FUMARATE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SLEEP INITIATION AND MAINTENANCE DISORDERS;

EID: 84975257655     PISSN: 13899457     EISSN: 18785506     Source Type: Journal    
DOI: 10.1016/j.sleep.2016.04.003     Document Type: Article

References (29)

1. Pringsheim T., Gardner D.M. Dispensed prescriptions for quetiapine and other second-generation antipsychotics in Canada from 2005 to 2012: a descriptive study. CMAJ Open 2014, 2(4):E225-32.
2. Leucht S., Corves C., Arbter D., et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009, 373(9657):31-41.
3. Derry S., Moore R.A. Atypical antipsychotics in bipolar disorder: systematic review of randomised trials. BMC Psychiatry 2007, 7:40.
4. Bertisch S.M., Herzig S.J., Winkelman J.W., et al. National use of prescription medications for insomnia: NHANES 1999-2010. Sleep 2014, 37(2):343-349.
5. Schutte-Rodin S., Broch L., Buysse D., et al. Clinical guideline for evaluation and management of chronic insomnia in adults. J Clin Sleep Med 2008, 4(5):487-504.
6. Park S. Off-label use of atypical antipsychotics: lack of evidence for their use in primary insomnia. Formulary 2013, 48(11):361-376.
7. Shah C., Sharma T.R., Kablinger A. Controversies in the use of second generation antipsychotics as sleep agent. Pharmacol Res 2014, 79:1-8.
8. Anderson S., Vande Griend J. Quetiapine for insomnia: a review of the literature. Am J Health Syst Pharm 2014, 71:394-402.
9. McCall C., McCall W.V. What is the role of sedating antidepressants, antipsychotics, and anticonvulsants in the management of insomnia?. Curr Psychiatry Rep 2012, 14(5):494-502.
10. Maher A.R., Maglione M., Bagley S., et al. Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis. JAMA 2011, 306(12):1359-1369.
11. Moher D., Shamseer L., Clarke M., et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 2015, 4(1):1.
12. Higgins J., Green S. Cochrane handbook for systematic reviews of interventions version 5.1.0 [Internet] [accessed 10.06.15]. http://handbook.cochrane.org/.
13. Balshem H., Helfand M., Schünemann H.J., et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol 2011, 64(4):401-406.
14. Tassniyom K., Paholpak S., Tassniyom S., et al. Quetiapine for primary insomnia: a double blind, randomized controlled trial. J Med Assoc Thai 2010, 93(6):729-734.
15. Wiegand M.H., Landry F., Brückner T., et al. Quetiapine in primary insomnia: a pilot study. Psychopharmacology (Berl) 2008, 196(2):337-338.
16. Juri C., Chana P., Tapia J., et al. Quetiapine for Insomnia in Parkinson Disease. Clin Neuropharmacol 2005, 28(4):185-187.
17. David D., De Faria L., Mellman T. Adjunctive risperidone treatment and sleep symptoms in combat veterans with chronic PTSD. Depress Anxiety 2006, 23:489-491.
18. Nanda F., Singer C. Placebo-controlled trial of quetiapine for sleep disturbance in dementia. Am J Geriatr Psychiatry 2009, 17(3):S1.
19. Singer C. Placebo-controlled trial of quetiapine for sleep disturbance in AD. Alzheimer's Dement 2011, 7(4):S773.
20. Williams S., Alinejad N., Williams J., et al. Statistically significant increase in weight caused by low-dose quetiapine. Pharmacotherapy 2010, 30:1011-1015.
21. Cates M.E., Jackson C.W., Feldman J.M., et al. Metabolic consequences of using low-dose quetiapine for insomnia in psychiatric patients. Community Ment Health J 2009, 251-254.
22. Choosing Wisely Treating sleep problems [accessed 10.06.15]. http://www.choosingwisely.org/patient-resources/treating-sleep-problems/.
23. Choosing Wisely Canada Thirteen things physicians and patients should question [accessed 21.07.15]. http://www.choosingwiselycanada.org/recommendations/psychiatry/.
24. Bauer M., McIntyre R.S., Szamosi J., et al. Evaluation of adjunct extended-release quetiapine fumarate on sleep disturbance and quality in patients with major depressive disorder and an inadequate response to on-going antidepressant therapy. Int J Neuropsychopharmacol 2013, 16(8):1755-1765.
25. Locklear J.C., Svedsäter H., Datto C., et al. Effects of once-daily extended release quetiapine fumarate (quetiapine XR) on quality of life and sleep in elderly patients with major depressive disorder. J Affect Disord 2013, 149(1-3):189-195.
26. Sheehan D.V., Locklear J., Svedsa H. Long-term functioning and sleep quality in patients with major depressive disorder treated with extended-release quetiapine fumarate. Int Clin Psychopharmacol 2012, 239-248.
27. Datto C., Svedsater H., Locklear J., et al. Effect of extended-release quetiapine fumarate on quality of life and sleep in elderly patients with generalized anxiety disorder. Neuropsychiatry 2013, 3(6):577-585.
28. Endicott J., Svedsäter H., Locklear J.C. Effects of once-daily extended release quetiapine fumarate on patient-reported outcomes in patients with generalized anxiety disorder. Neuropsychiatr Dis Treat 2012, 301-311.
29. Sheehan D.V., Svedsäter H., Locklear J.C., et al. Effects of extended-release quetiapine fumarate on long-term functioning and sleep quality in patients with Generalized Anxiety Disorder (GAD): data from a randomized-withdrawal, placebo-controlled maintenance study. J Affect Disord 2013, 151(3):906-913.